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Abstract  
AIMS The microbiome is the term used for the symbiotic microbial colonisation of 
healthy organs. Studies have found bacterial identifiers within voided urine which is 
apparently sterile on conventional laboratory culture, and accordingly there may be 
health and disease implications 
METHODS The International Consultation on Incontinence Research Society (ICI-
RS) established a literature review and expert consensus discussion focussed on the 
increasing awareness of the urinary microbiome, and potential research priorities.  
RESULTS The consensus considered the discrepancy between findings of 
conventional clinical microbiology methods, which generally rely on culture 
parameters predisposed towards certain “expected” organisms. Discrepancy 
between selective culture and RNA sequencing to study species-specific 16S 
ribosomal RNA is increasingly clear, and highlights the possibility that protective or 
harmful bacteria may be overlooked where microbiological methods are selective. 
There are now strong signals of the existence of a ‘core’ urinary microbiome for the 
human urinary tract, particularly emerging with ageing. The consensus reviewed the 
potential relationship between a patient’s microbiome and lower urinary tract 
dysfunction, whether low-count bacteriuria may be clinically significant and 
mechanisms which could associate micro-organisms with lower urinary tract 
symptoms.  
CONCLUSIONS Key research priorities identified include the need to establish the 
scope of microbiome across the range of normality and clinical presentations, and 
gain consensus on testing protocols. Proteomics to study enzymatic and other 
functions may be necessary, since different bacteria may have overlapping 
phenotype. Longitudinal studies into risk factors for exposure, cumulative risk, and 
emergence of disease need to undertaken. 
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Introduction 
“Microbiota” refers to the assemblage of microorganisms present in a defined 
environment. This is a crucial part of the “microbiome”, which can be used to refer to 
the entire habitat, including the microorganisms (bacteria, archaea, lower and higher 
eurkaryotes, and viruses), their genomes, and the surrounding environmental 
conditions (1). The concept of a microbiota contrasts with infection, where pathogenic 
bacteria trigger an inflammatory immune response. The microbiome of the gut has 
been well documented (2), but less is known about the urinary microbiome.  It is 
understood that for health, maintenance of the normal microbiome is essential (3) 
and this not only impacts on the risk of infection by pathogenic organisms, but is also 
likely to be implicated in the occurrence of immune mediated disease and 
carcinogenesis (4).  Additionally the urinary or bladder microbiome may contain 
microbially encoded functions, which when expressed may be beneficial or 
detrimental to the host. 
Sterility of healthy urine is thought to be maintained by host factors, of which the most 
important are;  
1. Anatomical: the physical barriers between the source of pathogenic bacteria 
and the urinary tract 
2. Urodynamic: ongoing flow of urine through the urinary tract, and complete 
bladder emptying when voiding 
3. Anti-microbial: antibodies, proteins and factors that kill or restrict the ability of 
the microbes to infect 
Urinary Tract Infection (UTI) is a common clinical problem, in which organisms are 
able to establish infection by expression of pathogenic features and/or impairment of 
at least one of the host defences. Conventionally, urine is considered to be sterile, 
illustrated by the frequent absence of bacterial growth when urine is cultured from 
asymptomatic individuals and in the diagnostic setting. However, key studies using 
new techniques have found bacterial identifiers within voided urine which is 
apparently sterile when subjected to conventional laboratory culture, taken from 
patients with no associated symptoms of infection (5, 6). 
The International Consultation on Incontinence Research Society (ICI-RS), meeting 
in Bristol in 2015, considered the emerging awarness of the urinary microbiome, 
discussing what potential links lie between urinary microbiota and urinary tract 
pathology, and identifying high priority research questions.  
Is urine sterile? 
Conventional microbiological methods using culture do not capture the full spectrum 
of urine bacterial species; growth conditions and culture media significantly affect 
bacterial yield, and organisms unable to grow in standard culture conditions will not 
be detected, e.g. anaerobic organisms. Potentially, the presumed sterility of urine 
may actually reflect the insensitivity of current routine culture methods. When non-
culture based methods were used to study the urinary microbiota in mid stream urine 
(MSU) samples from 16 asymptomatic healthy individuals (26-90 years old), a very 
different picture emerges from that seen with culture on conventional media. 454 
pyrosequencing of the 16S rRNA gene in conjunction with quantitative PCR (qPCR) 
of the 16S rRNA gene in urine samples allows measures of diversity and 
enumeration of the bacterial loads of each sample. The total number of genera 
identified from each person with respect to age was highly variable, and a total of 94 
genera were obtained (6). Of these, over two thirds would not be routinely cultivated 
or not reported individually by standard microbiological investigations. Females had a 
more heterogeneous mix of bacterial genera than males and more typically had 
representatives of the phyla Actinobacteria and Bacteroidetes. Both genders were 
mainly dominated by the phylum Firmicutes. Some age specific genera were also 
identified, i.e. Jonquetella, Pavimonas, Proteiniphilum and Saccharofermentans. 
Other separate studies have independently reported urinary bacteria using 16S rRNA 
gene sequencing (7, 8).  
This preliminary data indicates that the human urinary tract is not ‘sterile’, but 
possesses a ‘core’ urinary microbiome, and that about two thirds of these bacteria 
would not be seen with conventional culture methods. The finding of a wide range of 
bacterial RNA is of interest, but this does not mean the presence of viable organisms. 
Instead the RNA identified could mean previous exposure, with long-lasting 
persistence of breakdown products, but not necessarily ongoing bacterial influence. 
Nonetheless, the reporting of the ability to culture bacteria using enhanced 
microbiological methods which are less selective for anticipated bacteria (9) suggests 
that some of these bacteria may be viable. Further research in this area is essential 
to understand better the role of a healthy urinary microbiome for bladder and urinary 
tract health, and how alterations to this with ageing might affect the balance between 
health and disease. 
Does a patient’s Microbiome predict or reflect lower urinary tract dysfunction?  
Some studies support an epidemiological association between the human urine 
microbiome and lower urinary tract symptoms (LUTS) or incontinence. The presence 
of significant bacteriuria in women strongly correlates with all storage symptoms 
(nocturia OR 3.56, p=0.02, urgency OR 6.66, p=0.01, urgency incontinence OR 2.92, 
p=0.046, nocturnal enuresis OR 4.21, p=0.01) and bladder pain (OR 2.82, p=0.049). 
Bacteriuria was significantly associated with all aforementioned symptoms apart from 
urgency incontinence even after adjustment for age, parity, symptomatic prolapse, 
menopausal status and history of mid-urethral sling surgery (10). Amongst women 
with LUTS who had no acute frequency and dysuria, one out of five was found to 
have a positive MSU culture and one out of four sterile pyuria (11). Most of these 
women had overactive bladder syndrome (OAB) symptoms (74%). On the more 
obvious side, women who develop UTIs suffer significantly higher urine loss 
compared to those who do not experience UTIs (mean rate of urine loss x4.6/month 
as opposed to x2.6/month, p=0.04, in postmenopausal women).  Further, among 
those who developed a UTI, the rate of urine loss was x1.5 higher during the first 
three days of a clinical UTI (12).  
Distinguishable microbiota have now been identified between pure urgency urinary 
incontinence (UUI) or predominantly UUI patients and those with predominantly or 
entirely stress urinary incontinence (SUI). The latter two groups, however, appear to 
have significantly less diverse microbiota than the former two. In addition, the 
presence of bacterial DNA in the urine is associated with increased frequency of UUI 
episodes (13).  
Controlled data suggest a greater number of bacterial species in women with UUI 
compared to non-UUI women, but also differences in the diversity of the bacterial 
species (14).  The use of novel laboratory techniques, such as 16S rRNA gene 
sequencing and an exhanced culture protocol (expanded qualitative urine culture – 
EQUC), has allowed the identification of bacterial species which may not be 
detectable with the currently used microbiology analysis techniques (9). Accordingly, 
it has been found that non-UUI women may have more lactobacilli species than UUI 
women, while Aerococcus and Gardnerella species are more prevalent in UUI 
patients (14). Futher to higher mean daily number of UUI episodes, women who were 
sequence-positive for urine bacteria were younger (55.8 vs 61.3 years old; p=0.0007) 
and had a higher body mass index (33.7 vs 30.1 kg/m2; p=0.0009).  
Two recent studies have reported observations on the associations between urine 
microbiota and response to treatment of UUI. Responders to solifenacin treatment 
were more likely to have fewer bacteria and a less diverse bacterial community at 
baseline than non-responders (15). Sequence-positive women responded better to 
Botulinum neurotoxin-A treatment and were less likely to experience a UTI post-
instrumentation (16). However, more information is needed to interpret the 
relationship between the patient’s microbiome and likely response to treatment of 
lower urinary tract dysfunction.    
Is low-count bacteriuria clinically significant after all?  
The term “bacteriuria” signifies the presence of bacteria in the urine, but where there 
are comparatively low bacterial numbers on culture, their presence may be 
disregarded as non-significant clinically. Nontheless, a prospective, cross-sectional 
study of prevalence of bacteriuria ≥103 CFU/ml on catheter specimens showed that 
incontinent women were four times more likely to have bacteriuria compared to 
continent controls, with 2 out of 3 bacteriuric specimens growing ‘low-count’ 
bacteriuria.  The presence of bacteriuria was strongly associated with urodynamic 
increased bladder sensation (17). Further, following the use of enhanced culture 
techniques which could identify bacteriuria ≥102 CFU/ml, polymicrobial cultures were 
grown in 69% of chronic LUTS patients which were previously not considered with 
the standard MSU technique (18). The study of shed urothelial cells also allowed 
identification of several uropathogens, distinct between patients with chronic LUTS 
and controls (19). In light of such findings, considerations were raised about the 
clinical value of currently used MSU culture techniques, while the implications for 
further research into the clinical significance of low-count bacteriuria are obvious.   
Mechanisms associating micro-organisms with LUTS/OAB  
Studies during acute UTIs have demonstrated invasion by Escherichia coli into the 
cytoplasm of urothelial cells both in animals and humans, with persistence of long-
term intracellular bacterial reservoirs (20). Similarly, controlled studies of patients 
suffering from chronic LUTS showed that Enterococcus faecalis could subvert and 
invade the host urothelium; 75% of specimens from chronic LUTS patients had 
evidence of urothelial cell colonization, as opposed to 17% of the control samples 
(21).  Increased apoptosis of urothelial cells noted in patients with increased pyuria is 
a possible mechanism for increased exposure of the underlying mucosal layer to 
irritative actions and, in consequence, to the generation of LUTS. Chronic 
inflammatory findings in a large proportion of OAB bladder specimens with 
inflammatory cells present in the lamina propria in 98.4% of cases could be a pointer 
to such a mechanism (22).  
Another mechanism may involve host antimicrobial peptides (AMPs) which are 
essential components of normal host innate immune responses against infection and 
pathogen-induced inflammation. Studies of urine specimens from female pelvic floor 
surgery participants demonstrated significant correlations between UTI risk and both 
specific urinary microbiota and beta-defensin AMP levels. In addition, urinary AMP 
hydrophobicity and protease activity were greater in participants who developed UTI, 
and correlated positively with both UTI risk and symptoms (23).  
Inflammatory markers are sometimes increased in patients with OAB (24), but no 
clear link with infection has been established. Nonetheless, in both UTI and OAB, the 
prostaglandin (PG) system has been studied as a possible marker or modulating 
system. Increased urinary levels of Prostaglandin E2, (PGE2) and cyclo-oxygenase 
(COX-2) expression correlate with UTI and inflammatory processes, such as those 
induced by Bacillus Calmette Guerin (BCG) (25). Patients in whom UTI was treated 
with antibiotics have reduced urinary PGE2 compared with those who have active 
disease (25). The role of prostaglandins in bladder control and in OAB has been the 
focus of many studies. PG receptors  EP1 and EP2 are present in the urothelium, the 
detrusor and intramural ganglia of the guinea pig urinary bladder (26-29). Moreover, 
in vitro animal studies have shown that PGE2 has an effect on non-voiding 
contractions of the urinary bladder (30). 
Clinical studies have shown urinary PGE2 levels to be significantly higher in OAB 
patients (31, 32). Furthermore, in patients with detrusor underactivity, the urinary 
level of PGE2 was decreased when compared to that of patients without detrusor 
underactivity (32). In addition, the urine PGE2 levels negatively correlate with 
maximum bladder capacity in OAB patients (32). The serum PGE2 level was also 
shown to be increased in patients with OAB (33), with a significant decrease after 
intravesical botulinum neurotoxin-A treatment (33). Moreover, there has been the 
suggestion that patients with urgency urinary incontinence have higher serum PGE2 
versus those with continent OAB (34). Hence, PG-targeted therapy has been 
suggested for treatment of a variety of bladder dysfunctions (33). Clinical studies 
have shown that non-selective COX inhibitors flurbiprofen and indomethacin were 
associated with urodynamic and clinical benefits in a controlled study of 62 patients 
with detrusor overactivity (DO) (35, 36). Unfortunately, adverse effects such as 
nausea, vomiting, headache and gastrointestinal symptoms have prevented their use 
in the treatment of OAB (35, 36). A double-blind, placebo-controlled study of the non-
selective cyclooxygenase inhibitor ketoprofen (4 weeks intravesical treatment course) 
in 30 women with urodynamically proven DO showed complete relief of symptoms in 
18 patients, without adverse effects (37). 
PG-targeted therapy has also been explored for the treatment of underactive detrusor 
syndromes (38, 39).  In combination with the cholinergic agonist bethanechol 
chloride, intravesical instillation with PGE2 had limited therapeutic benefit compared 
to placebo (40). Other studies showed that intravesical instillation of PGE2 reduced 
the time to restoration of detrusor function after gynecological surgery (41, 42). 
To add another complicating factor, epigenetic causes of OAB need to be 
considered.  Epigenetics is the study of heritable changes in gene expression that 
are not caused by alterations in DNA sequence. Currently, there are virtually no 
studies on epigenetic changes and OAB. The infection of mammalian tissues with 
bacteria, viruses and other pathogens results in the modification of the host cell 
epigenome, particularly DNA methylation. In vitro infection of bladder urothelial cells 
with uropathogenic E. coli results in hypermethylation of the tumor suppressor gene 
CDKN2A, providing proof-of-concept that uropathogenic infection modulates the host 
cell epigenome (43). 
Future studies are needed to validate reported increased urinary PG levels in OAB, 
which might make them a useable biomarker for OAB.  In addition, further studies are 
needed to examine the value of agents influencing the PG system, such as COX 
inhibitors and EP receptor modulators, as a possible treatment of OAB. The 
intravesical route of drug administration would be an interesting subject of study to 
bypass the gastrointestinal side effects of these drugs.   
Research challenges 
New technologies for isolating and sequencing DNA are emerging, which are 
enhancing experimental opportunities and bringing down costs. Thus, there are 
considerable opportunities for developing the field, and rapid progress may now 
become possible. The ICI-RS meeting identified that it is very desirable to establish 
the scope of microbiome across the range of normality and clinical presentations, 
with epidemiological studies to identify whether any individual bacteria or synergistic 
associations are significant. The challenge is considerable and would need extensive 
resources, so there is a need for additional pilot research studies to support proof-of-
principle. Key to this is the importance of consensus on protocols, including the 
method of sample capture; voided urine is a convenient sample, but contains 
contributions from the entire urinary tract and perineum, which makes interpretation 
more complex and potentially open to question. Alternatives may require internal 
access, but  this is likely to be poorly accepted by patients, and difficult to employ in 
general healthcare.  
Little is known about what functions the microbiomic organisms provide in this niche. 
For example, is there a protective role for certain organisms equivalent to the vaginal 
Lactobacillus?  
Since there is functional overlap in protein expression between different bacterial 
genera, the need for proteomics to study enzymatic and other functions may be 
necessary. Such expression may be relevant where considering potential clinical 
concerns, such as whether bacteria are able to re-activate host conjugated toxins or 
carcinogens by enzymatic processes (or conversely whether they produce anti-
bacterial molecules which may afford protection against UTI pathogens, such as 
bacteriocins). 
Bacterial-host interactions are potentially crucial. Does the host genotype or 
phenotype affect which bacteria can have importance for disease generation or 
maintenance? Does alteration of microbiome have epigenetic effects? This will be a 
complex but fundamentally interesting challenge. Bacterial induction of secondary 
responses is also challenging but may be more achievable. For example, does 
altered serum or urinary PG levels reflect a secondary or mechanistic component in 
microbiomic generation of functional LUT disorders? 
Of course, a major interest lies in identifying whether there are there harmful 
organisms that can establish or maintain lower urinary tract disease. This may be in 
the form of a single organism, or a harmful combination. If such influence is identified, 
it raises the possibility to cure or prevent disease. Of course, it would be invaluable to 
know what mechanistic processes may drive the relevance- mediators, inflammation, 
or structural effects? 
Finally, the risk factors for exposure, insights into lifelong cumulative exposure risk, 
and the importance of key events (e.g. catheterisation, immunosuppression, 
menopause) have to be understood.  
Conclusions 
Modern techniques avoiding selective culture indicate the presumption of sterility of 
urine is potentially wrong. There are many potential consequences of microbial 
influence which may be important for generation of symptoms and disease, or 
conveivably may be protective. To establish the relationship will require considerable 
research progress, but the findings potentially could be rewarding for understanding 
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